EBNA1 Inhibitor Design via Virtual Screening and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inefficient in targeting and inhibiting the Epstein-Barr Nuclear Antigen 1 (EBNA1) protein, which is crucial for latent Epstein-Barr virus (EBV) infection and associated malignancies, due to the lack of specific inhibitors and the cost-inefficient traditional drug discovery processes.
Innovation Solution
Development of compounds with specific structures (Formula I, II, and III) that selectively inhibit EBNA1 protein-DNA binding activity, using high-throughput screening and molecular design techniques to identify and synthesize potent inhibitors for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug discovery processes are used to identify EBNA1 inhibitors, then comprehensive screening can be performed, but the process is cost-inefficient and time-consuming
Solution Approach 1:
The patent uses the known three-dimensional crystal structure of EBNA1 as a template to create virtual models for computational screening. This allows researchers to screen large libraries of compounds in silico before performing wet lab validation, significantly reducing the time and cost of traditional high-throughput screening while maintaining identification accuracy
Solution Approach 2:
The patent replaces the mechanical/physical process of traditional high-throughput screening with computational methods. By using molecular docking simulations and structure-based virtual screening, the system can evaluate thousands of compounds computationally, replacing the need for expensive and time-consuming physical screening assays
2Productivity
If high-throughput virtual screening is used to identify inhibitors, then cost and time efficiency improve, but specific and potent inhibitors may be missed without comprehensive screening
Solution Approach 1:
The patent divides the drug discovery process into distinct stages: initial virtual screening to identify candidate compounds, followed by iterative optimization cycles where compounds are synthesized, tested, and refined. This segmentation allows efficient filtering of large compound libraries while maintaining the ability to identify potent inhibitors through systematic improvement
Solution Approach 2:
The patent uses the EBNA1 three-dimensional structure as an intermediary between virtual screening and final inhibitor identification. The structural model serves as a bridge, allowing computational methods to effectively identify candidates that can then be validated experimentally, ensuring both efficiency and accuracy
3Object-affected harmful factors
If EBNA1 protein structure is targeted for inhibitor design, then specific inhibition of viral replication can be achieved, but the complexity of protein-DNA binding inhibition increases
Solution Approach 1:
The patent extracts the essential functional elements of EBNA1 from the full protein structure, focusing specifically on the DNA-binding domain and critical amino acid residues (such as Arg-167, Arg-168, Lys-171). By targeting these specific extracted elements rather than the entire protein, the design complexity is reduced while maintaining effective viral replication inhibition
Solution Approach 2:
The patent applies local quality by designing inhibitors that specifically target particular regions of the EBNA1 protein with high precision. Rather than attempting to inhibit the entire protein uniformly, the approach focuses on specific local sites critical for DNA binding and viral function, simplifying the overall design while achieving potent inhibition
Data Source
AI summary
The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.